SPOTLIGHT -
Andy Studna is an editor for Applied Clinical Trials, an MJH Life Sciences sister publication.
FDA Expands Indication for Gilead’s Biktarvy for HIV With Suppressed Viral Loads, Pre-Existing Resistance
Biktarvy approved for expanded indication to include patients with HIV who have suppressed viral loads with known or suspected M184V/I resistance.
Utility Therapeutics’ Antibiotic for Urinary Tract Infection Gets FDA Priority Review
Pivmecillinam has already been approved in Europe to treat uncomplicated urinary tract infections.
Phesi Releases Annual Analysis of Clinical Development for 2023
New analysis for 2023 shows signs of post-pandemic recovery; breast cancer remains most studied disease area.
Lessons Learned From the FDA's Regulation of Emerging Technologies
A commentary by former FDA Commissioner Scott Gottlieb, MD, addresses uncertainty regarding how the FDA will regulate new technologies, such as artificial intelligence.
IQVIA Responds to FTC’s Block on Acquisition of Propel Media
Proposed acquisition would have given IQVIA a market-leading position in healthcare advertising.
Identifying the Most Prevalent Challenges that Impact Product Launch Success
In-depth study outlines the top five reasons biopharma products miss launch forecasts.
The Promise and Challenges of Generative AI in Healthcare
Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of generative artificial intelligence can create the greatest benefits.
Kura Oncology, Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in Non-Small Cell Lung Cancer
Ongoing phase 1 dose-escalation trial of KO-2806 (FIT-001) for the treatment of patients with KRASG12C-mutated non-small cell lung cancer expected to begin dosing patients in combination with adagrasib by mid-2024.
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel for Severe Sickle Cell Disease
Exagamglogene autotemcel (exa-cel) has shown the potential to be a landmark therapy in preventing episodes of excruciating pain among patients with sickle cell disease.
New Beginnings: Sunlenca
Ushering in a novel class of drugs that attacks HIV at multiple stages of replication.
From Science to Strategy | 2023 Emerging Pharma Leader
How the pivot to corporate development became a natural fit for the once-destined scientist. (The story of Natasha A. Hernday, chief business officer of Seagen and a 2023 Emerging Pharma Leader.)
Industry Workforce Seeks Clarity
An evolving job market has forced life sciences companies to respond.
Announcing Our 2022 Emerging Pharma Leaders
In episode 108, the rest of the PharmExec editorial staff join Elaine and Miranda as they announce and give more insight into the profiles they've written about the eleven members of our 2022 Emerging Pharma Leaders.
Persistence Pays Off
An entrepreneurial quest to transform oncology treatment.
The ‘Grit’ to Get It Done
Fast riser in biotech strategy execution seizes on opportunities in immunotherapy.
Meeting the Patient—Virtually
Standard for reaching patients shifts with influx of new technology in post-COVID world.
Pharm Exec at 40 (2011-2014)
Looking Back at 2011–2014.
Formidable Option: Orgovyx
Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.
Announcing Our 2021 Emerging Pharma Leaders
Our editorial team presents the winners of our annual Emerging Pharma Leaders and their up-and-coming perspectives on a range of industry topics.
On the Fast Track
Script change from destined life in research to wild pace of biotech pays off.
Bullish on Breakthroughs
A passion for building the business engine behind treatments for rare disease.
Innovation Without Bounds
Launching a big pharma biotech incubator during the pandemic.
Pharm Exec at 40 (1990-1993)
Looking Back at 1990-1993.
Fingerpaint Names Schroen Lead of Photo 51
Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.
Smoothing Access Path
The role of advanced data technologies in reducing hurdles.
MJH Life Sciences' State of the Physician Survey: Financial Impact of COVID-19
In the second of MJH Life Sciences' State of the Physician reports, over 1,600 respondents weighed in on how they have been affected financially by COVID-19 and what it means for them moving forward.
MJH Life Sciences' State of the Physician Survey: Patient Communication During COVID-19
A new series of surveys has been released by MJH titled State of the Physician. The first focuses on how physicians are communicating with their patients during COVID-19.
Fingerpaint Launches New Consultancy Focused on Gene and Cell Therapies